Viromed Medical AG, a German medical technology company specializing in cold plasma technology, has received approval in Turkey for its medical device ViroCAP® med, classified as MDR Class IIa. The approval, announced via NEWMEDIAWIRE, allows the product to be used for medical applications in the Turkish market, particularly for the treatment of open wounds and intraoperative use.
The approval came earlier than expected; Viromed had anticipated it no sooner than February or March 2027. CEO Uwe Perbandt called it "a significant success for our international market development," noting that it follows the summer registration of ViroCAP® derma with Turkey's National Medical Device Tracking System (ÜTS). The company already holds binding minimum orders for 7,000 ViroCAP® derma/med devices through the end of 2028 for the Turkish market, with deliveries set to begin based on the new approval.
ViroCAP® med is designed for professional use by qualified medical personnel and supports contactless, mobile treatment of open wounds and intraoperative application of cold atmospheric plasma. Each application is planned to last one to two minutes while skin temperature remains below 40 degrees Celsius. The reimbursement process with Turkish health insurers is already running in parallel, which could ease adoption once commercial launch begins.
In addition to the Turkish milestone, Viromed and its partner Umeco have initiated approval processes for ViroCAP® med in additional Asian countries. A prerequisite for these efforts was the product's prior approval as an MDR Class IIa device in the EU; outside the EU, local approvals are required in each target country and are being pursued with distribution partners.
Viromed also reported its first reimbursement of ViroCAP® by a statutory health insurer. A selective contract was signed with a health insurer in Lower Saxony for an intensive care indication: treating patients with a left ventricular assist device (LVAD) to prevent infections at the driveline exit site. The company is in advanced discussions for further selective contracts with health insurers in three additional German federal states.
On the clinical front, a successfully completed retrospective study on the prevention of postoperative wound infections is scheduled for publication in November. Viromed is also launching a randomized study on ViroCAP® use in LVAD patients and another study on the technology's application in heart valves. More details on the company's operations are available through its www.viromed-medical-ag.de.
The approval and related progress matter for several reasons. Turkey represents a strategically important healthcare market, and the early approval accelerates Viromed's commercial launch there. The binding orders provide near-term revenue visibility, while the reimbursement process is critical to ensuring patient access. The first selective contract in Germany signals a potential pathway for broader reimbursement of cold plasma technology in Europe. Moreover, the parallel approval efforts in Asia and the expanding clinical program, including randomized trials, could strengthen the evidence base for ViroCAP® and support adoption in other indications. For investors and industry observers, these developments indicate execution on Viromed's international expansion strategy and may bolster confidence in the company's growth trajectory.
